Coronary Artery Bypass Graft News and Research

RSS

Racial disparities continue to exist in hospital readmissions, study finds

A new study in the journal Health Affairs shows that, despite being designed to more effectively manage care and control costs, black patients enrolled with Medicare Advantage are far more likely to be readmitted to the hospital after a surgery than those enrolled on traditional Medicare.

27 Jun 2017

Study compares cardiac repair potential of three types of stem cells

New research from New Zealand's University of Otago is providing fresh insights into how a patient's adult stem cells could best be used to regenerate their diseased hearts.

29 Nov 2016

Stents can be as effective as surgery for many patients with left main coronary artery disease

A major international study has found that drug-eluting stents, a less-invasive alternative to bypass surgery, are as effective as surgery for many patients with a blockage in the left main coronary artery.

1 Nov 2016

New analysis reveals ways to reduce patient's risk of postoperative pneumonia after cardiac surgery

Pneumonia is the most prevalent infection after open heart surgery, leading to longer hospital stays and lower odds of survival.

26 Jul 2016

Mortality risk proportional to PPM severity in aortic value surgery

Prosthesis-patient mismatch during surgical aortic valve replacement is associated with a perioperative mortality risk that increases with increasing PPM severity, study findings indicate.

3 Jun 2016

Study confirms under-utilization of medication in patients after bypass surgery

Researchers at Thomas Jefferson University discovered that nearly half of coronary artery bypass patients are not taking statins and aspirin together when they are referred for diagnostic cardiac catheterization at least three years after their initial bypass. Their results are currently in press online in the American Journal of Cardiology.

3 May 2016

Iroko announces availability of VIVLODEX capsules in U.S. pharmacies for patients with OA pain

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced today that VIVLODEX (meloxicam) capsules, a nonsteroidal anti-inflammatory drug (NSAID), is now available by prescription at pharmacies across the United States.

16 Feb 2016

Heart attack patients experiencing cardiogenic shock at higher risk of death in first 60 days post-discharge

Heart attack patients who experience cardiogenic shock have a higher risk of death or rehospitalization than non-shock patients in the first 60 days post-discharge, but by the end of the first year, the gap between the two groups narrows, according to a study published today in the Journal of the American College of Cardiology.

16 Feb 2016

Egalet, Teva sign agreement to commercialize SPRIX Nasal Spray in Israel, Gaza and the West Bank

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, today announced a collaboration agreement with Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company.

14 Dec 2015

Racial disparities exist for black and Hispanic patients undergoing major surgeries in U.S. hospitals

Considerable racial disparities exist in surgical outcomes for black and Hispanic patients undergoing major cancer and non-cancer surgeries in U.S. hospitals, even among institutions that have already enrolled in a national surgical quality improvement initiative.

9 Dec 2015

Older, low-income female patients less likely to complete cardiac rehabilitation after bypass surgery

Bypass patients who are older, female and/or from lower-income neighbourhoods are more likely to face delays in beginning cardiac rehabilitation (CR), making them less likely to complete CR, which can lead to a higher mortality risk, suggests a new study.

11 Nov 2015

Multimodal non-invasive neurological monitoring reduces postoperative delirium in older cardiac patients

Patients undergoing cardiac surgery are at an increased risk of developing delirium and other changes in cognitive function in the days following surgery. However, new research presented at the ANESTHESIOLOGY 2015 annual meeting, found using monitors to track depth of anesthesia and oxygenation levels in older patients' brains during cardiac surgery significantly reduced their incidence of postoperative delirium and associated cognitive decline.

28 Oct 2015

Egalet announces launch of OXAYDO (oxycodone HCI, USP) Tablets and IMPACT-Rx initiative

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing and commercializing innovative pain treatments, today announced the launch of OXAYDO (oxycodone HCI, USP) tablets -CII in the United States.

9 Sep 2015

Egalet to present scientific data on SPRIX Nasal Spray at Painweek 2015

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on discovering, developing, and commercializing innovative pain treatments, today announced that researchers will be presenting scientific data on SPRIX (ketorolac tromethamine) Nasal Spray, Egalet-001, an abuse-deterrent, extended-release, oral morphine product candidate, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone product in development, at PainWeek 2015 to be held September 8 to 12 in Las Vegas, Nevada.

1 Sep 2015

Statins reduce risk of death by 67% in CABG surgery

Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications.

1 Jun 2015

Study finds botulinum toxin injections in epicardial fat pads reduce AF risk immediately following surgery and after one year of follow-up

AF is the most common arrhythmia complicating cardiac surgery and occurs in approximately 30-40 percent of patients undergoing CABG surgery...

15 May 2015

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII.

25 Mar 2015

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014.

16 Mar 2015

FDA receives IDE application for CytoSorbents' CytoSorb cardiac surgery trial

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced today that it has submitted an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to conduct its proposed clinical trial using CytoSorb® intra-operatively in patients undergoing complex cardiac surgery requiring the use of a heart-lung machine.

31 Dec 2014

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic.

30 Dec 2014